Latest Strategy Changes News

FireFly Metals has agreed to sell its Ontario gold assets to Bellavista Resources for up to A$86.1 million in shares and performance rights, unlocking value for shareholders while focusing on its copper-gold growth strategy.

Hydrix Limited has amended its quarterly cash flow report, revealing stronger customer receipts and a stable cash position supported by robust financing facilities.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Axel REE Limited's latest magnesium sulphate leach tests at the Paraíso target confirm robust rare earth grades and a magnet-rich basket, underpinning a modular in-situ leach development at the Caladão Project in Brazil.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

F.F.I. Holdings anticipates a modest decline in half-year profit, citing one-off lease expenses despite steady food operations.

Pivotal Metals has revealed ore sorting test results at its Horden Lake project that deliver up to a 2.1 times uplift in copper grade, promising substantial cost savings and flexible development options in Quebec’s Tier 1 mining jurisdiction.

Cluey Ltd has terminated its planned acquisition of Education Futures Group, the parent of Art of Smart, citing unmet conditions. The company remains focused on expanding its blended learning offerings and exploring new acquisition opportunities.

Imagion Biosystems has submitted its Investigational New Drug application to the U.S. FDA for its MagSense® HER2 Imaging Agent, marking a pivotal step toward launching a Phase 2 clinical trial for breast cancer detection.

GrainCorp has lowered its FY26 earnings guidance, citing persistent global oversupply and weak grain prices that are squeezing margins and volumes. The agribusiness is accelerating cost controls while maintaining a strong balance sheet to navigate these headwinds.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.